ANWENDUNG DES HUMANBLUT-KOAGULATIONSFAKTORS-XIII ZUR BEHANDLUNG VON COLITIS GRAVIS

The use of human blood coagulation factor XIII for the treatment of ulcerative colitis is demonstrated in 4 representative cases. Treatment with factor XIII leads to rapid and total disappearance of the chief symptoms realizing transition to the remission stage.

Saved in:
Bibliographic Details
Main Authors URABE, MIKIO, CHUO-KU FUKUOKA-SHI FUKUOKA-KEN, JP, TANAKA, SATOSHI, HIGASHIKATSUSHIKA-GUN CHIBA-KEN, JP, TSUMURA, KENICHIRO, ICHIHARA-SHI CHIBA-KEN, JP
Format Patent
LanguageGerman
Published 19.05.1993
Edition5
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The use of human blood coagulation factor XIII for the treatment of ulcerative colitis is demonstrated in 4 representative cases. Treatment with factor XIII leads to rapid and total disappearance of the chief symptoms realizing transition to the remission stage.
Bibliography:Application Number: DE19883876817T